Accent Microcell Ltd (ACCENTMIC) — shareholding pattern, promoter holding, financials and share price
About Accent Microcell Ltd (ACCENTMIC)
Accent Microcell Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as ACCENTMIC and on the BSE under scrip code 92465. Its ISIN is INE0Q5D01013.
Incorporated in 2012, Accent Microcell Ltd manufactures Pharmaceutical Excipients [1]
Accent Microcell Limited specializes in manufacturing cellulose-based excipients primarily used in pharmaceuticals, nutraceuticals, food, and cosmetics. Their core products include Microcrystalline Cellulose (MCC), Spray Dried MCC, and Silicified Microcrystalline Cellulose (SMCC).
The company has a robust export footprint, contributing to over 53% of its revenue, indicating a strong presence in international markets. It has embarked on a strategic expansion to scale production and diversify product offerings.
Listed peers in Pharmaceuticals: Fredun Pharmaceuticals Ltd, Syncom Formulations (India) Ltd, Lincoln Pharmaceuticals Ltd, Fermenta Biotech Ltd, Bajaj Healthcare Ltd, Themis Medicare Ltd.
Valuation & Returns
10 Jul 2026At ₹513.45 a share on 10 Jul 2026, Accent Microcell Ltd (ACCENTMIC) was valued at a price-to-earnings ratio of 28.08x against an industry P/E of 36.41x and a price-to-book of 4.47x on a book value of ₹114.84 per share. Solomo computes return on equity of 15.92% and return on capital employed of 21.28% from filed results.
- P/E
- 28.08x
- Industry P/E
- 36.41x
- P/B
- 4.47x
- EPS (TTM)
- ₹18.65
- Book value / share
- ₹114.84
- ROE
- 15.92%
- ROCE
- 21.28%
- ROA
- 13.63%
- Debt / equity
- 0x
- Dividend yield
- 0.19%
- EBITDA margin
- 18.18%
- 52-week range
- ₹238 – ₹519.75
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Accent Microcell Ltd (ACCENTMIC) reported revenue of ₹349 crore, net profit of ₹44 crore and earnings per share of ₹18.28. That compares with revenue of ₹265 crore and net profit of ₹33 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹210 crore and net profit ₹26 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 166 | 197 | 246 | 265 | 349 |
| Net profit (₹ cr) | 6 | 12 | 30 | 33 | 44 |
| EPS (₹) | 4.01 | 8.26 | 12.57 | 13.78 | 18.28 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 20.62% | 20.95% | 7.77% |
| Profit growth | 47.86% | 53.06% | 9.58% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 53.02% of Accent Microcell Ltd (ACCENTMIC) (down 2.45 pp QoQ). Market capitalisation was ₹1,232 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2024.
Largest disclosed public shareholders in Jun 2026: KANTILAL PACHAN VADIA 8.35%, MANOJ AGARWAL 2.32%, NEGEN UNDISCOVERED VALUE FUND 1.62%, AARTH AIF GROWTH FUND 1.15%, MANOJ AGARWAL (HUF) . 1.01%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 53.02% | - | - | - | - |
| Mar 2026 | 55.47% | - | - | - | - |
| Dec 2025 | 55.44% | - | - | - | - |
| Sep 2025 | 55.44% | - | - | - | - |
| Jun 2025 | 55.09% | - | - | - | - |
| Mar 2025 | 55.09% | - | - | - | - |
| Sep 2024 | 55.09% | - | - | - | - |
| Mar 2024 | 55.09% | - | - | - | - |